159 related articles for article (PubMed ID: 18528893)
21. Expression of S-100 protein in renal cell neoplasms.
Lin F; Yang W; Betten M; Teh BT; Yang XJ;
Hum Pathol; 2006 Apr; 37(4):462-70. PubMed ID: 16564922
[TBL] [Abstract][Full Text] [Related]
22. Immunohistochemical distinction of renal cell carcinoma from other carcinomas with clear-cell histomorphology: utility of CD10 and CA-125 in addition to PAX-2, PAX-8, RCCma, and adipophilin.
Mentrikoski MJ; Wendroth SM; Wick MR
Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):635-41. PubMed ID: 25279712
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical markers to distinguish between hemangioblastoma and metastatic clear-cell renal cell carcinoma in the brain: utility of aquaporin1 combined with cytokeratin AE1/AE3 immunostaining.
Weinbreck N; Marie B; Bressenot A; Montagne K; Joud A; Baumann C; Klein O; Vignaud JM
Am J Surg Pathol; 2008 Jul; 32(7):1051-9. PubMed ID: 18496143
[TBL] [Abstract][Full Text] [Related]
24. Renal tubulocystic carcinoma is closely related to papillary renal cell carcinoma: implications for pathologic classification.
Zhou M; Yang XJ; Lopez JI; Shah RB; Hes O; Shen SS; Li R; Yang Y; Lin F; Elson P; Sercia L; Magi-Galluzzi C; Tubbs R
Am J Surg Pathol; 2009 Dec; 33(12):1840-9. PubMed ID: 19898225
[TBL] [Abstract][Full Text] [Related]
25. Renal cell carcinoma marker (RCC-Ma) is specific for cutaneous metastasis of renal cell carcinoma.
Perna AG; Ostler DA; Ivan D; Lazar AJ; Diwan AH; Prieto VG; Reed JA
J Cutan Pathol; 2007 May; 34(5):381-5. PubMed ID: 17448192
[TBL] [Abstract][Full Text] [Related]
26. Expression of Pax-2 in human renal cell carcinoma and growth inhibition by antisense oligonucleotides.
Gnarra JR; Dressler GR
Cancer Res; 1995 Sep; 55(18):4092-8. PubMed ID: 7664285
[TBL] [Abstract][Full Text] [Related]
27. The usefulness of immunohistochemical markers in the differential diagnosis of renal neoplasms.
Zhou M; Roma A; Magi-Galluzzi C
Clin Lab Med; 2005 Jun; 25(2):247-57. PubMed ID: 15848735
[TBL] [Abstract][Full Text] [Related]
28. Renal cell carcinoma marker reliably discriminates central nervous system haemangioblastoma from brain metastases of renal cell carcinoma.
Ingold B; Wild PJ; Nocito A; Amin MB; Storz M; Heppner FL; Moch H
Histopathology; 2008 May; 52(6):674-81. PubMed ID: 18393979
[TBL] [Abstract][Full Text] [Related]
29. PAX2 and PAX8: useful markers for metastatic effusions.
Waters L; Crumley S; Truong L; Mody D; Coffey D
Acta Cytol; 2014; 58(1):60-6. PubMed ID: 24334997
[TBL] [Abstract][Full Text] [Related]
30. Recent immunohistochemical markers in the differential diagnosis of primary and metastatic carcinomas of the liver.
Gokden M; Shinde A
Diagn Cytopathol; 2005 Sep; 33(3):166-72. PubMed ID: 16078249
[TBL] [Abstract][Full Text] [Related]
31. Hyaline globules in renal cell carcinoma and hepatocellular carcinoma. A clue or a diagnostic pitfall on fine-needle aspiration?
Nayar R; Bourtsos E; DeFrias DV
Am J Clin Pathol; 2000 Oct; 114(4):576-82. PubMed ID: 11026104
[TBL] [Abstract][Full Text] [Related]
32. [Pax-2 antigen expression in kidney tumours].
Vjestica JM; Marković-Lipkovski J; Tulić CD; Djokić MR; Segar BS; Cirović SL; Stojanović MM; Vuksanović AM
Acta Chir Iugosl; 2011; 58(4):15-20. PubMed ID: 22519185
[TBL] [Abstract][Full Text] [Related]
33. Utility of CD10 and RCCma in the diagnosis of metastatic conventional renal-cell adenocarcinoma by fine-needle aspiration biopsy.
Simsir A; Chhieng D; Wei XJ; Yee H; Waisman J; Cangiarella J
Diagn Cytopathol; 2005 Jul; 33(1):3-7. PubMed ID: 15945081
[TBL] [Abstract][Full Text] [Related]
34. Are heterogenous results of EGFR immunoreactivity in renal cell carcinoma related to non-standardised criteria for staining evaluation?
Langner C; Ratschek M; Rehak P; Schips L; Zigeuner R
J Clin Pathol; 2004 Jul; 57(7):773-5. PubMed ID: 15220376
[TBL] [Abstract][Full Text] [Related]
35. Oncocytic papillary renal cell carcinoma with solid architecture: mimic of renal oncocytoma.
Mai KT; Kohler DM; Robertson SJ; Belanger EC; Marginean EC
Pathol Int; 2008 Mar; 58(3):164-8. PubMed ID: 18251779
[TBL] [Abstract][Full Text] [Related]
36. Expression of brachyury in hemangioblastoma: potential use in differential diagnosis.
Barresi V; Vitarelli E; Branca G; Antonelli M; Giangaspero F; Barresi G
Am J Surg Pathol; 2012 Jul; 36(7):1052-7. PubMed ID: 22446946
[TBL] [Abstract][Full Text] [Related]
37. Utility of PAX8 and PAX2 immunohistochemistry in the identification of renal cell carcinoma in diagnostic cytology.
Knoepp SM; Kunju LP; Roh MH
Diagn Cytopathol; 2012 Aug; 40(8):667-72. PubMed ID: 22807381
[TBL] [Abstract][Full Text] [Related]
38. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study.
Zhai QJ; Ozcan A; Hamilton C; Shen SS; Coffey D; Krishnan B; Truong LD
Appl Immunohistochem Mol Morphol; 2010 Jul; 18(4):323-32. PubMed ID: 20216401
[TBL] [Abstract][Full Text] [Related]
39. Expression of GLUT1 in primary renal tumors: morphologic and biologic implications.
Ozcan A; Shen SS; Zhai QJ; Truong LD
Am J Clin Pathol; 2007 Aug; 128(2):245-54. PubMed ID: 17638658
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical analysis of monoclonal antibodies to renal antigens. Application in the diagnosis of renal cell carcinoma.
Oosterwijk E; Ruiter DJ; Wakka JC; Huiskens-van der Meij JW; Jonas U; Fleuren GJ; Zwartendijk J; Hoedemaeker P; Warnaar SO
Am J Pathol; 1986 May; 123(2):301-9. PubMed ID: 3706491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
